SEC-sourced researchBeta
BIOE
Bio Essence Corp
Company comparison ↗
Data passport
- CIK
- 0001723059
- Exchange
- OTC
- Business activity
- Pharmaceutical Preparations · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Nov 17, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 323,940.0000 | Mar 27, 2026 |
| December 2025 | 1,897,566.0000 | Mar 27, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 1,897,566.0000 | 896,197.0000 | 1,569,753.0000 | 422,474.0000 | 2,495,367.0000 | Mar 27, 2026 |
| December 2024 | 323,940.0000 | -1,308,796.0000 | 623,865.0000 | 281,024.0000 | 3,250,114.0000 | Mar 27, 2026 |
Explainable fundamental score
Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.
80/100
Profitability100
Growth100
Balance sheet0
Cash generation100
Data coverage100
Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $1.9M | Jan 1, 2025 – Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Previous period revenueRevenues | $323.94K | Jan 1, 2024 – Dec 31, 2024 | Mar 27, 2026 | 10-K |
| Net incomeNetIncomeLoss | $896.2K | Jan 1, 2025 – Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.57M | Jan 1, 2025 – Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Total assetsAssets | $422.47K | Dec 31, 2025 | Mar 27, 2026 | 10-K |
| Total liabilitiesLiabilities | $2.5M | Dec 31, 2025 | Mar 27, 2026 | 10-K |